Middle ear and mastoid glomus tumors (glomus tympanicum): An algorithm for the surgical management
Middle ear and mastoid glomus tumors (glomus tympanicum): An algorithm for the surgical management
复制标题
DOI：
10.1016/j.anl.2010.03.006
复制
发表时间：
2010-12-01
影响因子：
1.7
通讯作者：
Bacciu, Andrea
中科院分区：
文献类型：
--
作者：
Sanna, Mario;Fois, Paolo;Bacciu, Andrea
目的：血管球瘤是生长缓慢的良性病变，是中耳最常见的原发性肿瘤。本研究的目的是报告我们的手术策略在鼓室球tumors.Methods的管理：1988年12月至2008年7月，68例经组织学证实的鼓室球瘤进行了手术治疗。结果：本组病例按菲施和Mattox分型，A型44例（64.7%），B型24例（35.3%）。所有44例A类肿瘤均通过镫骨切除型经肛入路或耳后经肛入路安全切除。5例B类肿瘤患者通过经乳突入路进行手术。19例较大的B类肿瘤患者接受了岩部次全切除术，并进行了外耳道盲囊闭合和中耳闭塞。所有68例患者均实现了肿瘤的大体全切除。在1例病例中（1.4%），9年后复发，患者再次手术。在其余的patients.Conclusion：手术切除鼓室球瘤是一个安全的程序，允许肿瘤全切除，发病率最低，复发率低，并发症发生率低，没有残留/复发已被检测到在计算机断层扫描。(C)2010爱思唯尔爱尔兰有限公司版权所有。
Objective: Glomus tumors are slow-growing benign lesions and represent the most common primary neoplasms of the middle ear. The objective of the present study is to report our surgical strategy in the management of glomus tympanicum tumors.Methods: Between December 1988 and July 2008, 68 patients with histologically confirmed glomus tympanicum tumor underwent surgical treatment. The follow-up of the series ranged from 6 to 194 months (mean, 33.4 months).Results: Distribution of tumors according to Fisch and Mattox classification was as follows: type A, 44 cases (64.7%); type B, 24 cases (35.3%). All of the 44 Class A tumors were safely removed via either a stapedectomy-type transcanal approach or a retroauricolar-transcanal approach. Five patients with Class B tumors were operated on through a transmastoid approach. Nineteen patients with larger Class B tumors underwent a subtotal petrosectomy with blind sac closure of the external auditory canal and middle ear obliteration. Gross total tumor removal was achieved in all 68 cases. In one case (1.4%) there was recurrence after 9 years, for which the patient was re-operated. No residual/recurrence has been detected on computed tomography in the rest of the patients.Conclusion: Surgical excision of glomus tympanicum tumors is a safe procedure, allowing total tumor removal with minimal morbidity, a low recurrence rate, and a low complication rate. (C) 2010 Elsevier Ireland Ltd. All rights reserved.